Patent SG-11201905699X-A (SG)
Title: Anti-icos agonist antibodies and uses thereof
Inventor: ENGELHARDT JOHN
IPC: C07K16/28
Filed: 2018-04-05
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT ~~ll~~~~~~~~ 011101010VIIIOH oI0 OH1110IIIII011101110111111mow (10) International Publication Number WO 2018/187613 A2 (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2018/026318 (22) International Filing Date: 05 April 2018 (05.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/483,158 07 April 2017 (07.04.2017) US 62/514,151 02 June 2017 (02.06.2017) US 62/545,732 15 August 2017 (15.08.2017) US 62/581,412 03 November 2017 (03.11.2017) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 & Province Line Road, Princeton, NJ 08543 (US). (72) Inventors: ENGELHARDT, John, J.; 700 Bay Road, Redwood City, CA 94063 (US). SELBY, Mark, J.; 700 Bay Road, Redwood City, CA 94063 (US). KORMAN, Alan, J.; 700 Bay Road, Redwood City, CA 94063 (US). FEINGERSH, Mary, Diane; 700 Bay Road, Redwood City, CA 94063 (US). STEVENS, Brenda, L.; 1027 23rd Avenue E., Seattle, WA 98112 (US). (74) Agent: REMILLARD, Jane, E. et al.; Nelson Mullins Ri- ley & Scarborough LLP, One Post Office Square, Boston, MA 02109-2127 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: - without international search report and to be republished upon receipt of that report (Rule 48.2(g)) with sequence listing part of description (Rule 5.2(a)) N co 00 O C (54) Title: ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF (57) : The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen- specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.